ProBioGen AG, a Berlin-based contract development and manufacturing organization (CDMO) for developing and manufacturing complex therapeutic glycoproteins, has appointed Dr. Lutz Hilbrich as chief executive officer, effective June 1, 2020.
 
Hilbrich was recently vice president, head of biosimilars platform, Sanofi China. He is a seasoned leader with strong international experience, particularly in the U.S., China and Europe. He spent his last 20 years with two major pharmaceutical companies, Boehringer Ingelheim and Sanofi.
 
Dr. Wafik Bardissi, chairman of ProBioGen’s Supervisory Board and chairman and CEO of the parent company Minapharm Pharmaceuticals stated, “This is the perfect time for Lutz Hilbrich to become ProBioGen’s next chief executive officer. We selected a very strong leader at a time when ProBioGen is in an excellent position. I am very pleased to welcome Lutz as our new CEO.”
 
“I am delighted to join ProBioGen and lead the company to its next phase of expansion. For more than 25 years, I have been committed to Healthcare, to positively impacting people’s lives,” commented Hilbrich. “With its strong scientific base, ProBioGen is uniquely positioned to make a difference through developing cutting-edge technologies and manufacturing complex therapeutic antibodies and glycoproteins for its customers either highly innovative Biotech, Big Pharma or Biosimilar companies from around the globe. The strong ties with Egypt’s Minapharm bear huge potential and I am extremely attracted by the prospect of further driving ProBioGen’s expansion and footprint in new markets.”